FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996128181> ?p ?o ?g. }

• W2996128181 abstract "Second-line therapy randomized trials with lopinavir/ritonavir question the value of resistance testing to guide nucleoside reverse transcriptase inhibitor (NRTI) selection. In this study, we investigated the association between baseline drug resistance and treatment outcome after 104 weeks of second-line therapy with NRTIs and either darunavir/ritonavir or lopinavir/ritonavir in West-central Africa. We did an observational analysis of data from 387 individuals in a randomized, open-label 2LADY trial in Burkina Faso, Cameroon, and Senegal. We modeled the association between RTI drug resistance mutations (DRMs) and virological failure (VF) (viral load [VL] <50 copies/mL) at week 104 using logistic regressions. Covariates included baseline VL and CD4+ count, demographic, and adherence data. Overall, 193 (49.9%), 150 (38.8%), and 44 (11.4%) individuals had, respectively, low/none (genotypic susceptibility score [GSS] <1), intermediate (GSS = 1), and high predicted NRTI activity (GSS >1) in their prescribed second-line regimen. The average number of DRMs by drug class, the proportion of individuals by GSS category, and the duration of first-line therapy were not associated with VF (p > .05). High VL at switch was the only consistent prognostic factor for VF after multivariate adjustment (p < .01). Suboptimal adherence, high predicted RTI activity, or low NRTI mutations were associated with VF (p < .05) when using higher end points for VF or in the intention-to-treat analysis. In conclusion, the use of RTIs with predicted reduced activity does not impair second-line protease inhibitor-based therapy. Therefore, HIV care in resource-limited settings should prioritize strategies to improve adherence and targeted VL testing over drug resistance testing for selecting NRTIs during a protease-based second-line switch." @default.
• W2996128181 created "2019-12-26" @default.
• W2996128181 creator A5015663884 @default.
• W2996128181 creator A5017902016 @default.
• W2996128181 creator A5024849121 @default.
• W2996128181 creator A5025754562 @default.
• W2996128181 creator A5038842430 @default.
• W2996128181 creator A5054142063 @default.
• W2996128181 creator A5058617930 @default.
• W2996128181 creator A5069849746 @default.
• W2996128181 creator A5080065932 @default.
• W2996128181 creator A5081984235 @default.
• W2996128181 date "2018-06-01" @default.
• W2996128181 modified "2023-09-26" @default.
• W2996128181 title "Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir" @default.
• W2996128181 cites W1542566721 @default.
• W2996128181 cites W1916574222 @default.
• W2996128181 cites W2028301729 @default.
• W2996128181 cites W2053431870 @default.
• W2996128181 cites W2113027692 @default.
• W2996128181 cites W2338494325 @default.
• W2996128181 cites W2610986922 @default.
• W2996128181 cites W2612187578 @default.
• W2996128181 cites W2618258744 @default.
• W2996128181 doi "https://doi.org/10.1089/aid.2017.0290" @default.
• W2996128181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29575909" @default.
• W2996128181 hasPublicationYear "2018" @default.
• W2996128181 type Work @default.
• W2996128181 sameAs 2996128181 @default.
• W2996128181 citedByCount "4" @default.
• W2996128181 countsByYear W29961281812019 @default.
• W2996128181 countsByYear W29961281812020 @default.
• W2996128181 countsByYear W29961281812021 @default.
• W2996128181 crossrefType "journal-article" @default.
• W2996128181 hasAuthorship W2996128181A5015663884 @default.
• W2996128181 hasAuthorship W2996128181A5017902016 @default.
• W2996128181 hasAuthorship W2996128181A5024849121 @default.
• W2996128181 hasAuthorship W2996128181A5025754562 @default.
• W2996128181 hasAuthorship W2996128181A5038842430 @default.
• W2996128181 hasAuthorship W2996128181A5054142063 @default.
• W2996128181 hasAuthorship W2996128181A5058617930 @default.
• W2996128181 hasAuthorship W2996128181A5069849746 @default.
• W2996128181 hasAuthorship W2996128181A5080065932 @default.
• W2996128181 hasAuthorship W2996128181A5081984235 @default.
• W2996128181 hasConcept C114851261 @default.
• W2996128181 hasConcept C126322002 @default.
• W2996128181 hasConcept C142462285 @default.
• W2996128181 hasConcept C159047783 @default.
• W2996128181 hasConcept C168563851 @default.
• W2996128181 hasConcept C2777182164 @default.
• W2996128181 hasConcept C2777351918 @default.
• W2996128181 hasConcept C2779182219 @default.
• W2996128181 hasConcept C2779298103 @default.
• W2996128181 hasConcept C2780404665 @default.
• W2996128181 hasConcept C2781143361 @default.
• W2996128181 hasConcept C2781392899 @default.
• W2996128181 hasConcept C2781413609 @default.
• W2996128181 hasConcept C2993143319 @default.
• W2996128181 hasConcept C3013748606 @default.
• W2996128181 hasConcept C54355233 @default.
• W2996128181 hasConcept C71924100 @default.
• W2996128181 hasConcept C86803240 @default.
• W2996128181 hasConcept C98274493 @default.
• W2996128181 hasConceptScore W2996128181C114851261 @default.
• W2996128181 hasConceptScore W2996128181C126322002 @default.
• W2996128181 hasConceptScore W2996128181C142462285 @default.
• W2996128181 hasConceptScore W2996128181C159047783 @default.
• W2996128181 hasConceptScore W2996128181C168563851 @default.
• W2996128181 hasConceptScore W2996128181C2777182164 @default.
• W2996128181 hasConceptScore W2996128181C2777351918 @default.
• W2996128181 hasConceptScore W2996128181C2779182219 @default.
• W2996128181 hasConceptScore W2996128181C2779298103 @default.
• W2996128181 hasConceptScore W2996128181C2780404665 @default.
• W2996128181 hasConceptScore W2996128181C2781143361 @default.
• W2996128181 hasConceptScore W2996128181C2781392899 @default.
• W2996128181 hasConceptScore W2996128181C2781413609 @default.
• W2996128181 hasConceptScore W2996128181C2993143319 @default.
• W2996128181 hasConceptScore W2996128181C3013748606 @default.
• W2996128181 hasConceptScore W2996128181C54355233 @default.
• W2996128181 hasConceptScore W2996128181C71924100 @default.
• W2996128181 hasConceptScore W2996128181C86803240 @default.
• W2996128181 hasConceptScore W2996128181C98274493 @default.
• W2996128181 hasLocation W29961281811 @default.
• W2996128181 hasLocation W29961281812 @default.
• W2996128181 hasLocation W29961281813 @default.
• W2996128181 hasLocation W29961281814 @default.
• W2996128181 hasOpenAccess W2996128181 @default.
• W2996128181 hasPrimaryLocation W29961281811 @default.
• W2996128181 hasRelatedWork W1912089629 @default.
• W2996128181 hasRelatedWork W1965300563 @default.
• W2996128181 hasRelatedWork W1986196348 @default.
• W2996128181 hasRelatedWork W2036116759 @default.
• W2996128181 hasRelatedWork W2051976738 @default.
• W2996128181 hasRelatedWork W2108000358 @default.
• W2996128181 hasRelatedWork W2123055341 @default.
• W2996128181 hasRelatedWork W2588855433 @default.
• W2996128181 hasRelatedWork W2611234483 @default.
• W2996128181 hasRelatedWork W2996128181 @default.
• W2996128181 isParatext "false" @default.
• W2996128181 isRetracted "false" @default.

• next